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Biogenic metallic elements in the human brain?
James Everett1,2, Frederik Lermyte2,3, Jake Brooks2, Vindy Tjendana-Tjhin2, Germán Plascencia-Villa4, 
Ian Hands-Portman5, Jane M. Donnelly2, Kharmen Billimoria2,6,7, George Perry4, Xiongwei Zhu8, 
Peter J. Sadler6, Peter B. O’Connor6, Joanna F. Collingwood2, Neil D. Telling1*
The chemistry of copper and iron plays a critical role in normal brain function. A variety of enzymes and proteins 
containing positively charged Cu+, Cu2+, Fe2+, and Fe3+ control key processes, catalyzing oxidative metabolism 
and neurotransmitter and neuropeptide production. Here, we report the discovery of elemental (zero–oxidation 
state) metallic Cu0 accompanying ferromagnetic elemental Fe0 in the human brain. These nanoscale biometal 
deposits were identified within amyloid plaque cores isolated from Alzheimer’s disease subjects, using synchro-
tron x-ray spectromicroscopy. The surfaces of nanodeposits of metallic copper and iron are highly reactive, with 
distinctly different chemical and magnetic properties from their predominant oxide counterparts. The discovery 
of metals in their elemental form in the brain raises new questions regarding their generation and their role in 
neurochemistry, neurobiology, and the etiology of neurodegenerative disease.
INTRODUCTION
The transition metals iron and copper are essential for all organisms 
that undertake oxidative metabolism (1, 2) and, along with zinc, 
represent the three most abundant trace metals in the human brain 
(3). The ability of copper and iron to change oxidation state is cru-
cial for their biological functions (1, 4, 5). They act as important 
components of numerous enzymes that partake in redox reactions 
(1, 5, 6). While copper and iron are systemically used throughout 
the human body, with Cu and Fe proteins accounting for ca. 3% of 
the human proteome (7), the high energy demand of the brain has 
resulted in both of these elements being extensively used there 
during multiple physiological processes (5, 6).
Redox-active, catalytic copper and iron can generate toxic effects 
when they are incorrectly handled in the brain. The activity of avail-
able, “labile” copper and iron in Fenton-like redox chemistry results 
in the production of reactive oxygen species (ROS) such as hydroxyl 
radicals, capable of inducing oxidative stress and cell death (8–10). 
The chemically reduced Cu+ and Fe2+ can catalyze these reactions, 
further driving ROS production (10). Hence, copper and iron ho-
meostasis are tightly regulated in human tissues (5, 6, 11, 12).
Previous investigations into metal neurochemistry have shown 
that iron oxides exist within human brain tissues (5, 13–15). Nota-
ble is the discovery by Kirschvink et al. (14) of single-domain nano-
crystals of the chemically reduced, magnetic iron mineral magnetite 
extracted from postmortem brain tissue. Subsequent studies have 
revealed in situ evidence for this mineral within tissues (16). Fur-
ther understanding of metal homeostasis in the brain, and, in par-
ticular, the role of specific oxidation states in biomineralization, 
requires chemically sensitive measurements at nanoscale resolution.
Despite the discovery of nanoparticulate biogenic magnetite in 
the human brain almost 30 years ago (14), information on iron and 
copper biomineralization at physiologically relevant spatial scales in 
the brain remains scarce, with observations being limited to micro-
organisms, viruses, and plants [reviewed by Huang et  al. (17)]. 
These processes include the formation of elemental metallic (zero–
valent/oxidation state) nanoparticles from more oxidized precur-
sors [e.g., (18–21)], which are much more reactive than their oxide 
counterparts (22). This enhanced reactivity has been exploited in a 
range of applications, from catalysis to environmental remediation 
as well as antimicrobial activity (16, 23–25).
Disruptions to brain metal homeostasis have been implicated in 
the development of multiple neurodegenerative disorders including 
Alzheimer’s disease (AD) (26–28), the most prevalent form of de-
mentia worldwide, currently afflicting over 25 million people (29–31). 
More specifically, altered copper and iron homeostasis has been 
linked to the formation of amyloid plaques (32–36), a hallmark patho-
logical lesion of AD believed to be fundamentally involved in disease 
pathogenesis (29, 37, 38). Amyloid plaques from the AD brain con-
tain chemically reduced iron oxide phases that are potentially neuro-
toxic and may contribute to disease progression (15, 39).
Here, we use synchrotron-based scanning transmission x-ray 
microscopy (STXM; see fig. S1 for microscope schematic) to deter-
mine the nanoscale spatial distribution and chemical state of copper 
and iron within human amyloid plaque cores from two AD sub-
jects. STXM can generate chemically specific images to ca. 20-nm 
spatial resolution while simultaneously providing detailed x-ray 
absorption spectra, allowing the precise chemical state of a sample 
to be assigned as a function of two-dimensional space. This tech-
nique requires no staining of the sample with either dyes or contrast 
agents used in conventional imaging techniques, while careful con-
trol of x-ray exposure conditions ensures that the biochemistry of 
the samples is not disturbed (15, 39, 40). In addition, using circular-
ly polarized x-rays, it is possible to correlate the magnetic properties 
of regions of interest to their specific chemical speciation via the 
x-ray magnetic circular dichroism (XMCD) effect. Using these ap-
proaches, we found nanoscale deposits of elemental metallic copper 
(Cu0) and magnetic elemental iron (Fe0) within human brain tissue. 
To the best of our knowledge, this represents a first discovery of Cu0 
within human tissue. This discovery raises intriguing new questions 
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about the production and role of metal nanoparticles in the brain 
and whether their formation is linked to neuropathological processes.
RESULTS AND DISCUSSION
Amyloid plaque cores were isolated from the gray matter of the 
frontal and temporal lobes of two (Braak stage VI) AD brains. The 
full methodology used to obtain, isolate, and identify amyloid 
plaque structures is in Materials and Methods. Isolated amyloid 
plaques were embedded in a STXM-compatible resin and sec-
tioned to either 500 or 200 nm thickness for STXM analysis.
STXM analysis of three resin-embedded amyloid plaque cores 
from the two different AD subjects are shown below. For analysis, 
we adopted a multimodal x-ray absorption–based approach, de-
signed to exploit the nanoscale chemical sensitivity of STXM. Single- 
energy x-ray images were used to locate amyloid plaques and 
establish overall plaque morphology. X-ray metal maps allowed the 
identification of the metal, its oxidation state, and its distribution 
within the amyloid plaque. Metal oxidation state difference maps 
provided a qualitative distribution of differing metal oxidation states, 
showing (nanoscale) variations in metal chemistry. Magnetically 
sensitive XMCD maps were used to identify strongly magnetic metal 
deposits. X-ray absorption spectromicroscopy was then used to de-
termine the precise chemical state of individual metal deposits 
through the generation of location-dependent x-ray absorption 
spectra. This included magnetic characterization of metal deposits 
via XMCD x-ray spectromicroscopy. Full details on the acquisition 
of x-ray images, metal maps, and absorption spectra are in Materials 
and Methods and figs. S2 to S4.
Discovery of Cu0 in subjects also displaying evidence 
of chemically reduced iron
X-ray images, maps, and absorption spectra of an amyloid plaque 
core from subject X are shown in Fig. 1. The x-ray image in Fig. 1A 
shows the overall morphology of the plaque. The composite image 
in Fig. 1B shows the plaque copper and iron content. Copper maps 
(see also fig. S2) showed this plaque to contain multiple discrete 
deposits of copper in nanoscale deposits of both Cu2+ (Fig. 1B, 
green) and Cu+/Cu0 (i.e., Cu+ and/or Cu0; Fig. 1B, red).
Iron mapping showed that the amyloid plaque also contains nu-
merous nanoscale iron deposits (Fig. 1B, gray). High-resolution 
iron oxidation state difference mapping (Fig. 1C) shows a nanoscale 
variation in the oxidation state of amyloid plaque iron. The specific 
oxidation states of the iron deposits were determined from iron 
L2,3-edge x-ray absorption spectra.
Differing iron phases display markedly different spectral fea-
tures, as illustrated in the reference spectra in Fig. 1H. Specifically, 
ferric (Fe3+) materials display principal x-ray absorption features at 
709.5 and 723 eV, whereas ferrous (Fe2+) and zero–oxidation state 
metallic (Fe0) phases display features at 708 and 721 eV (41). Al-
though Fe2+ and Fe0 share absorption features at identical energies, 
Fe0 can be further distinguished from Fe2+ by its broadened absorp-
tion peaks and enhanced L2/L3 peak ratios (41). Iron x-ray absorp-
tion spectra (colored circles) and their respective fits (black lines) 
from the areas highlighted in Fig. 1C are displayed in Fig. 1F. Fitting 
showed area F1 to be composed of mixed oxidation states of Fe3+, 
Fe2+, and Fe0, while area F2 was predominantly Fe0.
The chemical state of the plaque copper was examined in more 
detail by collecting high-resolution Cu2+ and Cu+/Cu0 maps, 
oxidation state difference maps, and copper L2,3-edge x-ray absorp-
tion spectra for the area highlighted in Fig. 1B (yellow square; bot-
tom of image).
The resulting maps (Fig.  1,  D  and  E) show a nanoscale (hun-
dreds of nanometers) variation in copper speciation, with both oxi-
dized (Cu2+) and chemically reduced (Cu+/Cu0) phases present. 
Fig. 1. STXM images, metal maps, and iron and copper L2,3-edge x-ray absorp-
tion spectra of an amyloid plaque core from subject X. (A) STXM image showing 
the overall plaque morphology. (B) Composite STXM image showing plaque mor-
phology (blue), Cu2+ (green), Cu+/Cu0 (red), and iron (gray) content. (C) Iron oxida-
tion state difference map of the region highlighted in (B). Strongly absorbing 
oxidized iron (Fe3+) is shown as light contrast, and chemically reduced iron (Fe2+ 
and/or Fe0) is shown as dark contrast. (D) High-resolution composite image and 
(E) copper oxidation state difference map of the region highlighted in (B). In the 
oxidation state difference map, oxidized copper (Cu2+) is shown as light contrast, 
and chemically reduced copper (Cu+ and/or Cu0) is shown as dark contrast. (F) Iron 
x-ray absorption spectra from the regions highlighted in (C). (G) Copper x-ray ab-
sorption spectra from the regions highlighted in (E). Energies corresponding to 
Cu2+ and Cu+/Cu0 content are shown as dashed and dotted-dashed lines, respec-
tively. (H and I) Reference x-ray absorption spectra from iron and copper standards 
of varying oxidation states. (H) Iron L2,3-edge and (I) copper L2,3-edge. The energies 
corresponding to the oxidized and reduced states of the metals are shown by the 
dotted-dashed and dashed lines, respectively. Copper x-ray absorption spectra. 
Reprinted from Jiang et al. (42) with the permission of AIP Publishing.
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Copper x-ray absorption spectra from the areas highlighted in 
Fig. 1E are shown in Fig. 1G. As shown in the reference spectra in 
Fig. 1I, Cu2+ materials display a sharp high-intensity peak at 931 eV 
and a further lower-intensity peak at 951 eV (42). In contrast, Cu+ 
and Cu0 materials display peaks ca. 2.5 eV higher than Cu2+ at 
933.5 and 953.5 eV (42). From these known spectral features, it can 
be seen that area G1 of the plaque contains a pure Cu2+ phase, 
whereas areas G2 to G6 show both Cu2+ and Cu+/Cu0 features. For 
areas G2 to G4, the Cu2+ peak is dominant over Cu+/Cu0, whereas 
in G5 they are approximately equal. In G6, the Cu0 peak becomes 
the dominant feature.
These results demonstrate the presence of both iron and copper 
in different chemically reduced states within the same amyloid 
plaque. The presence of copper in multiple oxidation states within 
an individual plaque suggests that redox cycling of copper may oc-
cur within these structures. A further amyloid plaque core from 
subject X was also found to contain chemically reduced copper, 
Cu+, shown in fig. S5.
The findings for subject X are supported by the analysis of an 
amyloid plaque from a second Alzheimer’s case (subject Y) shown 
in Fig. 2, where copper (Fig. 2B) and iron (Fig. 2C) were both pres-
ent. Here, iron permeates the plaque and copper is confined to a 
single detectable Cu+/Cu0 deposit. The copper x-ray absorption 
spectrum from this deposit (Fig. 2E; cyan trace) strongly resembles 
an elemental metallic Cu0 reference film (Fig. 2E; black trace) (42) 
with additional minor contributions from Cu2+. While the spectra 
for Cu+ and Cu0 share principal peak positions at 933.5 and 953.5 eV, 
metallic copper (Cu0) is discernible through the presence of well- 
defined extended x-ray fine structure (EXAFS) at 938 and 941.8 eV 
(42, 43). Cu0 is additionally distinguishable from Cu+ by its compa-
rably small absorption-edge steps and high post-edge absorption 
intensities (see also Fig. 1I) (42). This observation for subject Y is 
supported by evidence for elemental metallic Cu0 in the EXAFS 
data from subject X (Fig. 1, area G6).
Iron x-ray absorption spectra from iron-rich regions throughout 
the plaque showed spatial variation in the iron oxidation state (Fig. 2F), 
with iron predominantly present as Fe3+ (F1: Fig. 2, C and F) as well 
as reduced forms (F2 and F3: Fig. 2, C and F). This was not an iso-
lated finding for this subject: fig. S6 shows an additional plaque 
from subject Y exhibiting multiple inclusions of reduced iron.
Copper mapping of a further amyloid plaque from subject X 
(Fig. 3) showed the presence of a single Cu+/Cu0 deposit (Fig. 3B). 
The copper x-ray absorption spectrum from this deposit (Fig. 3E) 
displayed small absorption-edge steps and high post-edge absorp-
tion intensities representative of Cu0, but without the well-defined 
EXAFS seen in the metallic Cu0 spectrum shown in Figs.  1I and 
2E. This spectrum may therefore represent a mixed Cu0/Cu+ phase 
or a poorly crystalline Cu0 phase.
Discovery of ferromagnetic elemental iron
Iron mapping of the amyloid plaque in Fig. 3 revealed multiple dis-
crete areas of iron deposition. The strongest iron signal in the iron 
map(s) (Fig. 3C, high-resolution map in Fig. 3F) correlated with the 
region of dark contrast in the XMCD map (Fig. 3G), suggesting that 
this iron inclusion is magnetic. The iron x-ray absorption spectrum 
(Fig. 3H, green) from this dense iron area (H2) was composed pri-
marily of Fe0 (94%), with only a small (6%) Fe3+ contribution. In 
contrast, for area H1, the spectrum (Fig. 3H; orange) consisted of 
contributions from Fe3+ (91%) and Fe2+ (9%).
Elemental iron is one of only three transition metals that display 
strong ferromagnetism. Therefore, to confirm the presence of ele-
mental metallic Fe0, the fundamental magnetic properties of areas 
Fig. 2. STXM images, metal maps, and copper and iron x-ray absorption spectra from a subject Y amyloid plaque. (A) STXM image showing the overall plaque 
morphology. (B) Cu+/Cu0 map. (C) Iron map. (D) Composite STXM image showing plaque morphology (blue), Cu+/Cu0 (red), and iron (gray) content. (E) Copper x-ray 
absorption spectrum from the copper area highlighted in (B) (cyan trace) and a Cu0 reference (black trace). Reprinted from Jiang et al. (42) with the permission of AIP 
Publishing. The energies corresponding to Cu2+ and Cu+/Cu0 content are shown by the dashed and dotted-dashed lines, respectively. Asterisks highlight extended x-ray 
absorption fine structure (EXAFS) indicative of metallic copper (Cu0). (F) Iron x-ray absorption spectra from the areas highlighted in (C).
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H1 and H2 were probed by performing magnetically sensitive 
XMCD measurements (see Fig. 4 and Materials and Methods for 
further experimental details), in addition to usual iron mapping.
The corresponding circular polarization–dependent x-ray ab-
sorption spectra and accompanying XMCD spectra, along with 
those from a pure elemental Fe0 film standard, are shown in 
Fig. 5 (A and B). XMCD measurements of the predominantly ferric 
region, H1, showed no clear evidence of dichroism (i.e., no differ-
ence between the x-ray absorption obtained using the two different 
x-ray polarizations), suggesting that this region is not strongly mag-
netic. Conversely, the circular polarization–dependent x-ray absorp-
tion and XMCD spectra obtained from region H2 showed strong 
dichroism (~16%), resulting in a negative XMCD peak at ca. 708 eV 
and a smaller broad positive peak (<~5%) at ca. 721 eV. The shape 
and intensity of this magnetic dichroism resemble the spectra of a 
ferromagnetic metallic Fe0 film standard. Although not identical to 
the Fe0 reference film, any differences are consistent with the pres-
ence of an oxidized nonmagnetic component in the amyloid plaque 
iron rather than the formation of a magnetic iron oxide mineral 
phase such as magnetite or maghemite, which would produce a 
more complex three-peak XMCD spectra typical for these ferrimag-
netic biominerals (see fig. S7 and Supplementary Text) (15, 39). The 
strong intensity of the magnetic dichroism from this amyloid 
plaque iron also excludes the possibility of Fe-S compounds, which 
can have x-ray absorption and XMCD spectra similar in shape to 
metallic iron, but show a much weaker dichroism. For example, the 
most magnetic Fe-S mineral, pyrrhotite, was found to exhibit only a 
2.5% dichroism effect in a 500-mT field (more than twice the field 
strength used here) at equivalent x-ray energies (44). These obser-
vations show that this amyloid plaque iron is elemental metallic 
rather than a mineral form of iron.
XMCD measurements, performed on resin-embedded air-exposed 
Fe0 nanoparticle standards, yielded spectra consistent with oxida-
tion products of metallic iron, namely, the ferrimagnetic phases 
magnetite and maghemite (fig. S7 and Supplementary Text). This 
observation demonstrates how readily nanoscale Fe0 particles oxi-
dize in air. In turn, this indicates that plaque-bound iron, where it 
has been chemically reduced to metallic Fe0, is protected by amyloid 
encapsulation from postmortem auto-oxidation. The apparent ab-
sence of severe surface oxidation of nanoparticulate Fe0 within the 
amyloid plaques characterized here suggests that they are endoge-
nous, rather than exogenous postmortem contamination by partic-
ulate matter (PM). If the living brain acquired this iron as airborne 
PM (45), subsequent surface reduction would be necessary to ac-
count for the observed properties of the iron particles.
The results presented here appear to be the first to report ele-
mental metallic Cu0 and Fe0 in human tissue. The observation of 
these phases, apparently formed within amyloid plaque cores taken 
from the gray matter of human AD subjects, will stimulate new 
thinking about the role of metals in human neurobiology and may 
provide new insights into the etiology of Alzheimer’s and related 
neurodegenerative diseases.
The nanoscale chemical and magnetic specificities of STXM 
have allowed us to probe the biochemistry of human brain tissue on 
subcellular length scales. This enabled the detection of multiple dif-
ferent chemically reduced copper and iron phases within AD amy-
loid plaques, revealing nanoscale metallic deposits. Many studies 
have used microfocus x-ray spectroscopy to characterize metal 
chemistry in human tissues (33, 46). However, although chemically 
sensitive, the spatial resolution of these techniques leads to spatial 
averaging only across the micrometer scale, precluding the precise 
identification of the highly reduced nanoscale metal deposits observed 
Fig. 3. STXM images, metal maps, and copper and iron x-ray absorption spec-
tra from a subject X amyloid plaque core. (A) Overall plaque morphology. 
(B) Cu+/Cu0 map. (C) Iron map. (D) Composite STXM image showing plaque mor-
phology (blue), Cu+/Cu0 (red), and iron (gray) content. (E) Copper x-ray absorption 
spectrum from the copper deposit highlighted in (B). The energies corresponding 
to Cu2+ and Cu+/Cu0 content are shown by the dashed and dotted-dashed lines, 
respectively. (F) High-resolution iron map and (G) iron XMCD map from the region 
highlighted in yellow in (C). In the XMCD map, areas of bright and dark contrast 
represent the presence of magnetic iron. (H) Iron x-ray absorption spectra from the 
iron deposits highlighted in (C), (F), and (G).
Fig. 4. Schematic displaying the experimental setup for the magnetically sen-
sitive XMCD measurements. A magnet array was inserted into the rear face of the 
sample holder (magnetic field lines shown in orange), placing the sample (located 
on the front face of the holder) under a magnetic field of 250 mT. The incident x-ray 
beam was tuned to contain either left circularly polarized (LCP) or right circularly 
polarized (RCP) light. Sample regions were examined under both LCP and RCP 
light, with differences between these two measurements representing the XMCD 
effect (see also Materials and Methods).
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here. The ability to separate spatially different metal phases with 
nanoscale resolution using STXM techniques provides unique char-
acterization of copper and iron in tissues.
There are several plausible mechanisms for the formation of ele-
mental metallic Cu0 and Fe0 in amyloid deposits. The first is direct 
reduction of A-bound Cu+/2+ and Fe2+/3+. Given the reportedly 
high reduction potential of A-Cu composites compared to other 
biomolecule-Cu complexes, this is feasible (47). Supporting this, we 
collected in  vitro mass spectrometry (MS) data with collision- 
induced dissociation (CID) (see figs. S8 to S10 and Supplementary 
Text), which showed that A(1–42) binds Cu2+, in the N-terminal 
region. Analysis of the isotope distributions of Cu-bound fragments 
demonstrated that Cu2+ reduction to Cu+ occurs during the CID 
process. Accompanying a- and c-type peptide fragments, formed 
from hydrogen-deficient peptide cation radicals (48), were also ob-
served, providing direct evidence that A(1–42) acts as the reducing 
agent during the conversion of Cu2+ to Cu+. Thus, the reduction of 
copper by A(1–42) is a potential source of the chemically reduced 
Cu phases observed in AD amyloid plaque cores as evidenced 
by STXM.
Natural hydride donors such as NAD(P)H (reduced form of 
nicotinamide adenine dinucleotide phosphate) and formate may also 
be capable of reducing copper and iron to metallic forms. Other 
transition metals (notably, Ru, Os, and Ir) can accept hydride, al-
though no in vitro evidence yet exists for copper and iron. It is no-
table that enzymes containing iron-sulfur clusters use formate as an 
electron donor (49–51).
Multiple bacteria, fungi, and plants produce elemental metallic 
nanoclusters, including Cu0 and Fe0, as a means of resistance to 
metal toxicity (52–54). The mechanisms for these syntheses are not 
fully understood, but are thought to proceed through enzymatic 
reduction, in some cases coupled to the oxidation of glucose (53). 
There may be analogous reductases in the human brain, including 
cysteine-rich Zn2+- and Cu+-binding metallothionein-3, a neuropro-
tective protein with thiolate clusters, capable of reducing A-Cu2+ 
to A-Cu+ (55).
Because A-Cu2+ is readily reduced to A-Cu+ by multiple bio-
logical reductants (56), Cu0 nanoclusters might be formed through 
the disproportionation of A-bound Cu+ into Cu2+ and Cu0. Cu+ 
appears to prefer a linear or trigonal binding geometry to A (e.g., 
involving His13 and His14), in which it could readily bind O2 (57). 
Under conditions of hypoxia, which are related to neurodegenera-
tion and increased A accumulation (58), aggregates of A-Cu+ un-
able to bind O2 may instead destabilize and disproportionate to 
Cu2+ and Cu0.
Under conditions of oxidative stress, oxidative attack on coordi-
nated amino acids such as Cys or His could disrupt the Cu coordi-
nation sphere, destabilizing Cu+ toward disproportionation. Such 
oxidative attack is feasible in the context of the oxidative damage 
observed in AD brain tissue. Possible oxidants include ROS, such as 
hydroxyl radicals (produced, for example, by an A-Cu redox cycle) 
(57) and hypochlorous acid, which has been associated with amy-
loid burden in AD mouse models (59). This possibility is supported 
by the observation of oxidized Cu-binding amino acid residues 
(e.g., His6, His13, His14, and Tyr10) in A-Cu complexes in vitro 
(also shown in supporting MS data here) and A plaques from the 
brains of AD patients (57, 60).
A final intriguing possibility is the catechol- and phenol-oxidizing 
activity of A-Cu2+. There is evidence for a dinuclear Cu2+ center in 
A-Cu aggregates that is capable of both monooxygenase and oxi-
dase activity, similar to the catechol oxidase and tyrosinase enzymes 
(61). The proposed inactivation mechanism for tyrosinase occurs 
Fig. 5. XMCD measurements of a subject X amyloid plaque core. (A) LCP and RCP iron x-ray absorption spectra, and (B) XMCD spectra from the amyloid plaque iron 
shown in Fig. 3, and a thin Fe0 reference film.
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when oxy-tyrosinase processes a catechol as a phenol, triggering its 
monooxygenation to a hydroxyquinone rather than its oxidation to 
an ortho-quinone. This mechanism results in the reductive elimina-
tion of one Cu as Cu0 (62). Over time, in the presence of excess 
catechol, tyrosinase is gradually deactivated, as the buildup of Cu0 
limits the number of catalytically active Cu2+ centers. In the case of 
A-Cu2+, its oxidation of catecholamines like l-DOPA and dopa-
mine (both present in high concentrations in the brain) could result 
in a similar inactivation mechanism, producing Cu0 that is then sta-
bilized and protected from subsequent oxidation by the A aggre-
gate. The ability of A to stabilize copper in a Cu0 state would offer 
an explanation for the recently reported enrichment of isotopically 
light copper in AD brains compared to disease-free controls (63).
The accumulation of reduced metallic copper and iron observed 
here within amyloid plaques may induce oxidative stress through 
the localized overproduction of ROS (9, 10, 64, 65), thereby contrib-
uting to the pattern of neuroinflammation and neuronal failure in 
AD-affected brain areas. The presence of metallic elemental nano-
particles would be expected to further exacerbate these effects due 
to the increased reactivity of metallic phases compared to their 
oxide counterparts. Alternatively, the sequestering of redox-active 
and catalytically active metals by amyloid may represent an antiox-
idant mechanism by preventing metal-catalyzed oxidation of near-
by cellular structures (66). The process of amyloid plaque formation 
and degradation in human brains, for both healthy individuals and 
those with AD, remains to be fully elucidated.
Transition metals that can be associated with specific disease pa-
thologies offer potential for disease diagnosis and staging, particu-
larly with the application of advances in iron-sensitive clinical 
imaging (67). Chemically reduced copper and iron associated with 
amyloid structures may also represent an innovative target for alter-
native AD therapies intended to lower the oxidative stress burden 
in affected brain regions. While it is critical that metal-modifying 
strategies are not detrimental to essential metabolic processes de-
pendent on these elements, targeting the interaction of amyloid 
with copper and iron may alter neurotoxicity arising from this in-
teraction, thereby modifying disease progression.
The unexpected identification of Cu0 and Fe0 within AD amy-
loid plaques suggests that biogenic metallic elements, previously 
observed only in microorganisms, viruses, and plants, can also oc-
cur in humans. The reactivity of these metallic phases differs from 
their metal oxide counterparts previously detected in the human brain 
and has the scope to redefine our understanding of metal neurochem-
istry and the role of metal toxicity in neurodegenerative diseases.
MATERIALS AND METHODS
Preparation of amyloid plaque cores for STXM analysis
Human brain tissue was obtained from two AD subjects at autopsy 
with the informed written consent of their relatives. The methodol-
ogy used to obtain, isolate, and identify amyloid plaque structures 
from the brain tissue was approved by the Bioethics Committee 
(Department of Pathology, Case Western Reserve University), and 
this study was performed under U.K. ethical approval 07/MRE08/12 
and U.S. IRB 03-00-26. The process of amyloid plaque core prepa-
ration for STXM analysis has also been previously described by 
Everett et al. (15).
The brains from the two confirmed AD subjects (Braak stage VI) 
were removed at autopsy (5 hours postmortem), divided into half, 
cut into 1-cm slices, and stored at −70°C. The frozen tissue slices 
were thawed, and the gray matter from the frontal and temporal 
lobes was isolated through the removal of the blood vessels, meninges, 
and white matter. The isolated gray matter was then homogenized 
by heating to 95°C in the presence of 2% SDS in 50 mM tris buffer. 
This homogenate was filtered (100-m pore size) to remove any re-
maining large tissue debris and pelleted through centrifugation at 
800 rpm. AD gray matter was then further homogenized through 
the addition of 0.1% (w/v) SDS, 150 mM NaCl, and 0.02% NaN3 
(w/v) before being filtered (35 m pore size) and pelleted at 1000 rpm 
for ca. 30 min. Amyloid plaque cores were isolated from the filtrate 
through ultracentrifugation at 20,000 rpm in a sucrose gradient [1.8 to 
1.2 M sucrose, in a 0.1% (w/v) SDS, 150 mM NaCl, and 0.02% (w/v) 
NaN3 solution]. The resulting fractions were collected, before being 
recovered for a final time with 0.1% (w/v) SDS, 150 mM NaCl, and 
0.02% (w/v) NaN3, and concentrated via centrifugation at 1200 rpm.
Forty microliters of pelleted amyloid plaque core material was 
transferred into a centrifugal concentrator (Corning Spin-X UF; 
40-kDa cutoff) and spun at 6690 rpm for 10 min. Amyloid plaque 
cores were dehydrated through an ethanol series (100 l; 40 to 100% 
dry), with waste ethanol being removed at each step through cen-
trifugation at 6690 rpm for 10 min. No other chemical fixatives were 
introduced to prevent metal leeching and preserve mineral compo-
sition within the amyloid plaque cores. Following dehydration, am-
yloid plaque cores were embedded in an STXM-compatible resin 
composed of an equimolar mixture of trimethylolpropane triglyc-
idyl ether: 4,4′-methylenebis (2-methylcyclohexylamine). This res-
in has previously been used successfully by our group to examine 
biological tissues using x-ray spectromicroscopy (15, 39, 68–70). 
Resin polymerization occurred at 60°C over a period of 24 hours. 
Semi-thin sections, 500 or 200 nm thickness, of embedded amyloid 
plaque cores were cut with a Reichert-Jung Ultra-cut microtome, 
using a nonmetallic (diamond) blade to minimize the risk of metal 
contamination during the sectioning process. Sections containing 
embedded amyloid plaque cores were deposited onto transmission 
electron microscopy (TEM) grids (Agar Scientific; 100 mesh), and 
these grids were, in turn, mounted onto sample plates for STXM 
examination.
The presence of amyloid plaque material within the sectioned 
sample material was confirmed via staining with 1% (w/v) Congo 
red solution and subsequent examination using cross-polarized op-
tical microscopy as shown in figure 1 of Everett et al. (15). Congo 
red–stained sections were not used for STXM experiments.
Preparation of metal standards
Copper(II) oxide (CuO) nanopowder (<50 nm particle diameter) 
and Fe0 nanoparticles (25 to 45 nm diameter; both from Sigma- 
Aldrich) were embedded in an STXM-compatible resin composed 
of an equimolar mixture of trimethylolpropane triglycidyl ether, 
4,4′-methylenebis (2-methylcyclohexylamine), as used during the 
embedding of the amyloid plaque cores. Semi-thin sections (100 to 
500 nm thickness) of the embedded metal standards were cut with a 
Reichert-Jung Ultra-cut microtome using a diamond blade and were 
mounted onto TEM grids (Agar Scientific; 100 mesh) for STXM 
examination. Both the embedding and sectioning of the metal nano-
particles were performed under ambient conditions. These stan-
dards were prepared to assess the effect of the embedding process 
and to confirm that the STXM measurements did not alter the oxi-
dation state of metals embedded within an organic matrix. An 
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additional ferric (Fe3+) iron standard was also prepared in an organic 
polymer matrix [as described by Brooks et al. (68)] to further assess 
the effect on iron oxidation state of successive x-ray beam doses. To 
avoid cross-contamination of samples, the preparation of metal 
nanoparticle standards was performed after the preparation and 
storage of amyloid plaque core materials.
Scanning transmission x-ray microscopy
STXM experiments were performed at the Advanced Light Source 
(Lawrence Berkeley National Laboratory, CA, USA) beamline 11.0.2 
and Diamond Light Source (Oxfordshire, UK) beamline I08. Fo-
cused x-ray spot sizes were ≤50 nm at both sources. Single-energy 
x-ray images taken at the iron L3-edge (706 eV; fig. S6) or copper 
L3-edge (928 eV; Figs. 1 to 3 and figs. S2 and S5) were used to locate 
and visualize the overall morphology of the amyloid plaques.
STXM metal maps
To generate maps showing the spatial distribution of metal phases 
associated with the amyloid plaque cores, paired images were taken: 
one peak image at the energy corresponding to a feature of interest 
(e.g., the Cu2+ L3-edge peak; 931 eV) and a further off-peak image a 
few electron volts below this feature. The off-peak image was then 
subtracted from the peak image, yielding a metal map. This method 
of metal mapping, shown in fig. S2, allows artifacts from the embed-
ding resin to be removed, providing a true representation of the 
metal distribution within the amyloid plaque cores. By finely tuning 
the energy of the incident x-ray beam, metal distribution maps 
showing distinct oxidation states were generated by exploiting the 
preferential absorption of x-rays of differing energies by specific 
metal phases (e.g., Cu2+ at 931 eV and Cu+/Cu0 at 933.5 eV). Metal 
maps were created at the iron L3-edge (710 eV) showing iron distri-
bution and two energies at the copper L3-edge (ca. 931 and 933.5 eV) 
showing Cu2+ and Cu+/Cu0 content, respectively.
Additional iron and copper oxidation state difference maps were 
created by subtracting images taken at energies corresponding to a 
chemically reduced state (Fe2+/Fe0 [708 eV], Cu+/Cu0 [933.5 eV]) 
from the oxidized state (Fe3+ [709.5 eV], Cu2+ [931 eV]). The result-
ing maps provide a qualitative distribution of the different iron and 
copper oxidation states within the plaque, with reduced phases 
showing as dark contrast and oxidized phases showing as light con-
trast (see also fig. S3).
Metal x-ray absorption spectra
X-ray absorption spectra providing detailed information regarding 
the oxidation state of metal phases within the amyloid plaque cores 
were obtained from a series of images (called a “stack”) taken over a 
desired energy absorption edge (see fig. S4). Raw x-ray absorption 
intensities were normalized to the incident x-ray beam by conver-
sion to optical density using background regions that did not 
contain any sample material. Using this approach, specific x-ray 
absorption spectra can be generated from each pixel of an image, 
allowing the chemical composition of highly localized (<50 nm in 
this instance) regions of interest to be determined. Stacks were ac-
quired over the iron L2,3-edge (700 to 740 eV) and copper L2,3-edge 
(920 to 960 eV). For stack measurements, the dark count (back-
ground noise attributable to the beamline) was subtracted before 
the generation of the x-ray absorption spectra. When examining 
amyloid plaque material, dwell (exposure) times per pixel were 
kept as short as possible while ensuring sufficient signal:noise to 
minimize photon-dose effects, thereby negating any substantial 
alteration of native sample chemistry (see also the “Optimization 
of STXM scanning parameters” section and the Supplementary 
Materials).
Scanning transmission x-ray microscopy–x-ray magnetic 
circular dichroism
To establish the magnetic state of the iron inclusions identified with-
in the amyloid plaque cores, magnetically sensitive XMCD measure-
ments were performed. These measurements were facilitated by 
inserting a NdFeB ring magnet array (allowing x-ray transmission) 
into the rear face of the STXM sample holder and mounting the 
sample to the front face of the holder (see Fig. 4 for STXM-XMCD 
sample holder schematic and fig. S1 for STXM beamline schematic). 
The magnetic field strength at the sample position was measured to 
be ~250 mT, which we have previously shown is sufficient to induce 
a significant degree of magnetic polarization in iron mineral (e.g., 
magnetite) standards, as well as magnetic iron inclusions within 
amyloid plaque cores (15). X-ray absorption spectra from such mag-
netized samples were created by performing paired stacks over the 
iron L2,3-edge using both left and right circularly polarized (RCP) 
light. The dichroism is revealed as the difference spectrum obtained 
by subtracting the x-ray absorption spectra obtained using RCP 
light from the equivalent spectra obtained using left circularly po-
larized (LCP) light (see, e.g., fig. S7).
To visualize iron deposits showing strong magnetic polarization 
(i.e., strongly magnetic deposits), XMCD maps were also created. 
These were obtained by first averaging five images taken close to the 
Fe2+/Fe0 L3-edge peak energy position for both LCP and RCP mea-
surements. The averaged RCP image was then subtracted from the 
equivalent LCP image to yield an XMCD difference map, with areas 
of bright or dark contrast indicating significant dichroism effects 
(e.g., Fig. 3G).
Optimization of STXM scanning parameters
To best preserve the native chemistry of the amyloid plaque copper 
and iron upon examination with STXM, control measurements were 
first performed on ferric (Fe3+) and cupric (Cu2+) metal oxide stan-
dards to assess the effect of x-ray beam dose on the oxidation state 
of these metals.
The purpose of these control measurements was to ascertain 
STXM scan parameters that generate sufficient signal:noise to de-
termine metal oxidation state while simultaneously limiting x-ray 
doses to ensure negligible x-ray beam–induced changes to sample 
chemistry, thereby validating the use of these methodologies for the 
examination of metal oxidation state. This is typically achieved by 
tuning the incident beam intensity by, for example, increasing/
decreasing exposure (dwell) times or altering the beamline optics 
such as the exit slits. Because of the inherent variations in synchro-
tron light source specifications, the x-ray dose tolerance of sample 
materials, and the scientific questions under investigation, these pa-
rameters must be empirically tailored for each individual experi-
ment. The experiments described below demonstrate our method 
for optimizing the specific STXM scanning parameters used in 
this study.
To determine the optimal scan parameters for iron L-edge spec-
tromicroscopy, we performed a series of repeat iron L3-edge STXM 
measurements on a ferric standard within an organic polymer ma-
trix, using differing x-ray doses controlled by altering the beamline 
exit slit size. We determined an appropriate x-ray dose to be where 
no changes in the iron L3-edge spectra were observed over succes-
sive iron L3-edge measurements. Scans were performed with either 
10- or 5-m exit slit sizes. No perceivable changes to Fe3+ oxidation 
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state were observed in successive measurements using 5-m exit 
slits (see fig. S11 and Supplementary Text).
Using these 5-m exit slits, the stability of amyloid plaque core 
iron was assessed over four successive iron L2,3-edge measurements, 
performed as two paired XMCD measurements (as described in the 
previous section). No changes in amyloid plaque iron L2,3-edge 
spectra were observed over the four successive measurements, con-
firming these parameters to be suitable for assessing the chemical 
and magnetic state of amyloid plaque iron (see fig. S12 and Supple-
mentary Text).
To determine appropriate x-ray exposure (dwell) times for the 
examination of amyloid plaque copper, successive copper L2,3-edge 
measurements were performed on embedded CuO standards to as-
sess the effect of extended periods of high-energy beam exposure on 
the oxidation state of copper(II) (see fig. S13 and Supplementary 
Text). No perceivable changes to copper(II) oxidation state were 
observed over the measurements, with spectra representative of a 
pure Cu2+ material being generated in all instances, thereby vali-
dating the use of this methodology for the examination of copper 
oxidation state. Dwell times of <10 ms/pixel were used at both syn-
chrotron light sources.
STXM data processing
STXM data were processed using the aXis 2000 software package 
(http://unicorn.mcmaster.ca/aXis2000.html). Grayscale x-ray mi-
croscopy images were converted to false color and recombined as 
overlays to create pseudo-colored composite images. For each mea-
sured iron L2,3-edge x-ray absorption spectrum, the relative pro-
portion of different iron phases contributing to the spectrum was 
estimated by fitting the measured spectra to standards of Fe3+, Fe2+, 
Fe3O4, and Fe0 using a nonlinear least-squares fitting procedure, as 
described by Everett et al. (15). A total of 22 amyloid plaque cores 
were examined. The Fe0 reference spectrum used for fitting, dis-
played in Figs. 1 and 5, was obtained from Fe0 film standards pre-
pared and measured under vacuum to prevent oxidation (71).
Fourier transform ion cyclotron resonance  
mass spectrometry
MS experiments were performed on a 12-T solariX quadrupole/
Fourier transform ion cyclotron resonance (FTICR) instrument 
(Bruker Daltonik GmbH, Bremen, Germany) equipped with an in-
finity cell (72). Ions were introduced using nano-electrospray ion-
ization in positive ion mode and externally accumulated in a 
hexapole collision cell before being transferred to the ICR cell. For 
CID experiments, precursor ions were selected in the quadrupole, 
and a collision voltage of 25 V was applied. Data analysis was per-
formed using Bruker Compass DataAnalysis 4.1, and peaks were 
assigned manually. For this, at least two isotope peaks were observed 
to ascertain the ion’s charge state. Assignments were typically made 
with a mass accuracy better than 1 part per million (see table S1).
Samples were prepared in Milli-Q grade H2O containing 
25 mM ammonium acetate (Thermo Fisher Scientific, Loughborough, 
UK). A(1–42) (monoisotopic mass, 4511.27 Da) was purchased 
from Bachem (Bubendorf, Switzerland), and CuSO4 was acquired 
from Sigma-Aldrich (Dorset, UK). The concentration of both the 
peptide and CuSO4 was 12.5 M.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/24/eabf6707/DC1
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